Inflammation and atherosclerosis in acute coronary syndromes

Journal of Invasive Cardiology

Volumn 16, Issue 7, 2004, Pages 377-384

  Murtagh, Blaithnead M ^a   Anderson, H Vernon ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndromes; Inflammation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; RHO KINASE INHIBITOR; THIENO[2,3 B]PYRIDINE DERIVATIVE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE COURSE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; SYNDROME;

EID: 3042775302     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Behrendt D, Ganz P. Endothelial function: From vascular biology to clinical applications. Am J Cardiol 2002;90(Suppl):40L-48L.
2. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002;105:546-549.
3. Gauthier TW, Scalia R, Murohara T, et al. Nitric-oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1652-1659.
4. Cornwell TL, Arnold E, Boerth NJ, et al. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-1413.
5. de Graaf JC, Banga JD, Moncada S, et al. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-2290.
6. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
7. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: Implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002;95:89-100.
8. Verma S, Li SH, Badiwala MV, et al. Endothelium antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.
9. Kaplanski G, Martin V, Fabrigoule M, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998;92:1259-1267.
10. Schonbeck U, Libby P. CD40 signalling and plaque instability. Circ Res 2001;89:1092-1103.
11. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class AI/II and CD36 are the principle receptors responsible for the uptake of modified low density lipoproteins leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-49988.
12. Lippy P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
13. Cominacini L, Rigoni A, Fratta Pasini A, et al. The binding of oxidized low-density lipoprotein (oxLDD) to ox-LDL receptor-1 in endothelial cells reduces the intracellular concentration of nitric oxide through an increased production of superoxide. J Biol Chem 2001;276:13750-13755.
14. Griendling KK, Ushio-Fukai M, Lassegue B, et al. Angiotensin II signaling in vascular smooth muscle cells: New concepts. Hypertension 1997;29:366-373.
15. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation in human vascular smooth muscle cells. Atheroscler Thromb Vasc Biol 1999;19:1623-1629.
16. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: Potential link between the rennin-angiotensin system and atherosclerosis. Circulation 1999;100:1223-1229.
17. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
18. Szmitko PE, Wang C-H, Weisel RD, et al. New markers of inflammation and endothelial cell activity. Circulation 2003;108:1917-1923.
19. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
20. Hansson GK, Libby P. Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291.
21. Porreca E, DiFebbo C, Reale M, et al. Monocyte chemotactic protein-1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. J Vasc Res 1997;34:58-65.
22. Kataoka H, Kume N, Miyamota S, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectin-like ox-LDL receptor-1 in vascular smooth muscle cells. Atheroscler Thromb Vasc Biol 2001;21:955-960.
23. Carpenter KHL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett 2001;505:357-363.
24. Galis Z, Sukhova G, Lark M, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
25. Calabro P, Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-1932.
26. Pasceri V, Willerson JT, et al. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
27. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
28. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
29. Zwaka TP, Hombach V, Torzew J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implication for atherosclerosis. Circulation 2001;103:1194-1197.
30. Yeh ET, Anderson HV, Pasceri V, et al. C-reactive protein: Linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.
31. Nakogomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex and hormone replacement treatment. Circulation 2000;101:1785-1791.
32. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation 2002;105:2019-2023.
33. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global clinical risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
34. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135.
35. Jager A, van Hinsbergh VW, Kostense PJ, et al. Von Willebrand factor, C-reactive protein and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study. Atheroscler Thromb Vasc Biol 1999;19:3071-3078.
36. Festa A, D'Agostino R Jr., Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
37. Ridker PM, Buring JE, Cook N, Rifai. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
38. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: A population based study. Diabetes Care 2000;23:1835-1839.
39. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716.
40. Shilpak MG, Fried LF, Crump C, et al. Elevation of inflammatory and procoagulant biomarkers in elderly patients with renal insufficiency. Circulation 2003;107:32-37.
41. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
42. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with Troponin T in acute coronary syndromes: A TIMI IIA substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31:1460-1465.
43. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and Troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 Antiplatelet Therapy in Unstable Angina Refractory to Standard Treatment Trial. J Am Coll Cardiol 2000;35:1535-1542.
44. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin During Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-1147.
45. Mueller C, Buettner HJ, Hodgson JD, et al. Inflammation and long-term mortality after non ST-elevation acute coronary syndromes treated with a very early invasive strategy in 1,042 consecutive patients. Circulation 2002;105:1412-1415.
46. Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular disease? Arch Intern Med 2002;162:867-869.
47. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-1772.
48. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increased levels of interleukin (IL)-I Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079-2084.
49. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001;286:2107-2113.
50. Ridker PM, Rifai N, Pfeffer M, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-2153.
51. Lee Y, Lee WH, Lee SC, et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999;92:11-16.
52. Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD 154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-1054.
53. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
54. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998;394:200-203.
55. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-2268.
56. Aukrust P, Mueller P, Ueland T, et al. Enhanced level of soluble and membrane bound CD40 ligand in patients with unstable angina: Possible reflection of T-lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:1930-1932.
57. Scarbrough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists: Peptide antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem 1993;268:1066-1073.
58. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247-252.
59. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin and tissue factor. Circulation 1997;96:396-399.
60. Urbich C, Mallat Z, Tedgui A, et al. Upregulation of TRAF-3 by shear stress blocks CD40 mediated endothelial activation. J Clin Invest 2001;108:1451-1458.
61. Leitinger N, Watson AD, Hama SY, et al. Role of group II secretory phospholipase A2 in atherosclerosis. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999;19:1291-1298.
62. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-1284.
63. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-1155.
64. Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302-1306.
65. Ballantyne C, et al. Lipoprotein-associated phospholipase A2 and risk for incident coronary heart disease in middle-aged men and women in the ARIC study. Presented at the American College of Cardiology, April 2, 2003.
66. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of MMP-2 and MMP-9 are elevated in patients with acute myocardial syndrome. J Am Coll Cardiol 1998;32:368-372.
67. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of MMP-9 and TIMP-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217.
68. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum MMP-1 and MMP4 tissue inhibitor after successful reperfusion of acute coronary syndromes. Heart 1997;78:278-284.
69. Hojo Y, Ikeda U, Ueno S, et al. Expression of MMPases in patients with AMI. Jpn Circ J 2001;65:71-75.
70. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92kD gelatinase in human coronary atherosclerotic lesions. Associations of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-2131.
71. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345;1022-1094, 1099.
72. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule-1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
73. Shyu KG, Chang H, Lin CC, et al. Circulating ICAM-1 and E-selectin in patients with acute coronary syndromes. Chest 1996;109:1627-1630.
74. Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995;92:1693-1696.
75. Mulvihill NT, Foley JB, Ghaisas N, et al. Early temporal expression of soluble cellular adhesion molecules in unstable angina and subendocardial myocardial infarction. Am J Cardiol 1999;81:1265-1267.
76. Mulvihill NT, Foley JB, Murphy RT, et al. Inflammatory markers predicting outcome in unstable angina and non-Q wave myocardial infarction. Heart 2001;85:623-627.
77. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142.
78. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes. J Am Coll Cardiol 2002;40:1761-1768.
79. Johnson BD, Kap K, Ridker PM, et al. Relationship between serum amyloid A and coronary artery disease in women: The NHLBL-sponsored women's ischemic syndrome evaluation (WISE) study. J Am Coll Cardiol 2003;41(Suppl A):262A.
80. Sahara M, Ogasawara K, Aizawa T, et al. Serum-amyloid A low-density lipoprotein complex: A novel prognostic marker in stable coronary heart disease. J Am Coll Cardiol 2003;41(Suppl A):1098-1116.
81. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
82. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL-receptor deficient mice. Circulation 2002;105:1816-1823.
83. Scheuren N, Jacobs M, Ertl G, Schorb W. Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol 2002;34:29-37.
84. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-409.
85. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST elevation: The Nonsteroidal Anti-inflammatory Drug in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 2002;106:191-195.
86. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002;106:167-169.
87. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.
88. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;839-844.
89. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvostatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study. A randomized controlled trial. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. JAMA 2001;285:1711-1718.
90. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
91. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-379.
92. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306-1307.
93. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med 2001;345:1419-1421.
94. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Atheroscler Thromb Vasc Biol 1998;18:1671-1678.
95. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-I expression in human vascular endothelial cells. Hypertension 2000;36:325-329.
96. Chew DP, Bhatt DL, Robbins MA, et al. Effect of dopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-674.
97. Vivekananthan DP, Bhatt DL, Chew DP, et al. Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-reactive protein. J Am Coll Cardiol 2003;41(Suppl A):1075-1165.
98. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-2041.
99. Moshfegh K, Rodondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after MI: Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36:699-705.
100. Yusuf S, Zhao F, Mehta SR, et al. The clopidogrel in unstable angina to prevent recurrent events trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
101. Hsueh WA, Law RE. PPAR-gamma and atherosclerosis. Effects on cell growth and movement. Atheroscler Thromb Vasc Biol 2001;21:1891-1895.
102. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684.
103. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque stability. Circulation 2000;101:1372-1378.
104. Hoshida S, Kato J, Nishino M, et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndromes. Circulation 2001;103:630-633.
105. Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998;98:800-807.
106. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. SAVE Investigators. Circulation 1994;90:1731-1738.
107. Acute Infarction Ramapril Efficacy (AIRE) Study Investigators. Effect of Ramapril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
108. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-153.
109. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003;107:443-447.
110. Imhof A, Froelich M, Brenner H, et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001;104:1367-1373.
111. Rimm EB, Giovannucci EL, Willet WC, et al. Prospective study of alcohol consumption and risk of coronary artery disease in men. Lancet 1991;338:464-468.
112. Gaziano JM, Gaziano TA, Glynn RJ, et al. Light to moderate alcohol consumption and mortality in the Physician's Health Study enrollment cohort. J Am Clin Cardiol 2000;35:96-105.
113. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med 1995;332:1245-1250.
114. Maclure M. Demonstration of deductive meta-analysis: Ethanol intake and risk of myocardial infarction. Epidemiol Rev 1993;15:1-24.
115. Doll R, Peto R, Hall E, et al. Mortality in relation to consumption of alcohol: 13 years' observation on male British doctors. Br Med J 1994;309:911-918.
116. Constant J. Alcohol, ischemic heart disease, and the French paradox. Clin Cardiol 1997;20:420-424.
117. McCarthy MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty-acids, ethanol and pentoxiphylline. Med Hypoth 1999;52:465-477.
118. Ridker PM, Vaughan DE, Stampfer MJ, et al. Association of moderate alcohol consumption and plasma concentration of endogenous tissue type plasminogen activator. JAMA 1994;272:929-933.
119. Makamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: Analysis of the Framingham Offspring Cohort. Circulation 2001;104:1367-1373.
120. Stone AFM, Mendall MA, Kaski JC, et al. Effect of treatment for Chylamidia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes. Circulation 2002;106:1219-1223.
121. Nichol KL, Nordin J, Mullody J, et al. Influenza vaccination and reduction in hospitalization for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322-1332.
122. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-658.
123. Smith JK, Dykes R, Douglas JE, et al. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999;281:1722-1727.
124. Spanbroek R, Gräbner R, Lötzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003;100:1238-1243.
125. Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of Toll-like receptor-4 in the development of intimal lesions. Circulation 2002;106:1985-1990.